PLEASANTON, Calif., May 16, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the availability of Veeva Vault Basics, a new offering that includes technology, training, and support designed for biotechs. Vault Basics equips fast-growing companies to deploy industry-leading Veeva Vault applications with zero implementation and maintenance costs. Biotechs can quickly adopt applications built on industry best practices, establishing a foundation to scale and manage growth. Ten biotechs are live with Vault Basics to drive efficiency, speed, and compliance.
"Veeva Vault Basics delivers the complete, pre-validated solution that we need to operate quickly and efficiently as we scale our business," said Phil Adams, senior director of IT at Longboard Pharmaceuticals. "Adding proven technology that was easy to deploy allows us to remain nimble, reducing our ramp-up time, decreasing risk of non-compliance, and improving data quality to accelerate product time to market."
Biotechs using Vault Basics can manage end-to-end processes on Vault applications that are always up to date with the latest features and functionality. Vault Basics is available for North America today and includes:
"We're applying our deep expertise in life sciences to offer one of the only solutions purpose-built with the simple path biotechs need to scale for growth," said Steve Harper, general manager, Veeva Vault Basics. "With 10 biotechs already signed up and starting to see the benefits of Veeva Vault Basics, we're gaining momentum as more growing companies use Vault with significantly less effort, overhead, and ongoing maintenance."
Additional Vault Basics offerings are planned for availability in 2025. For more on Vault Basics, visit veeva.com/VaultBasics.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$213.78 |
Daily Change: | 3.15 1.50 |
Daily Volume: | 239,988 |
Market Cap: | US$34.620B |
November 20, 2024 November 19, 2024 October 24, 2024 September 05, 2024 September 05, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB